EUVIMEDEUVIMED entdecken
Open Access

Randomized optimal selection design for dose optimization

Shuqi Wang iD, Ying Yuan iD, Suyu Liu iD

Biometrics · 2025

DOI: 10.1093/biomtc/ujaf124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, 2025. Verfasst von Shuqi Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: Dose-Response Relationship, Drug, Maximum Tolerated Dose, Randomized Controlled Trials as Topic, Research Design. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: U.S. Food and Drug Administration, NCI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The US Food and Drug Administration (FDA) launched Project Optimus to shift the objective of dose selection from the maximum tolerated dose to the optimal biological dose (OBD), optimizing the benefit-risk tradeoff. One approach recommended by the FDA’s guidance is to conduct randomized trials comparing multiple doses. In this paper, using the selection design framework, we propose a Randomized Optimal SElection (ROSE) design, which minimizes sample size while ensuring the probability of correct selection of the OBD at pre-specified accuracy levels. The ROSE design is simple to implement, involving a straightforward comparison of the difference in response rates between two dose arms against a predetermined decision boundary. We further consider a two-stage ROSE design that allows for early selection of the OBD at the interim when there is sufficient evidence, further reducing the sample size. Simulation studies demonstrate that the ROSE design exhibits desirable operating characteristics in correctly identifying the OBD. A sample size of 15–40 patients per dosage arm typically results in a percentage of correct selection of the optimal dose ranging from 60% to 70%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dose-Response Relationship, DrugMaximum Tolerated DoseRandomized Controlled Trials as TopicResearch DesignHumansSample SizeComputer SimulationUnited StatesUnited States Food and Drug AdministrationBiometry

Stichwörter der Autor:innen

dose optimizationoptimal designrandomizationselection design

Autor:innen und Institutionen

  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

ORCID-Profile: Shuqi Wang, Ying Yuan, Suyu Liu

Förderung

  • U.S. Food and Drug Administration
  • NCI NIH HHS
  • NIDDK NIH HHS
  • National Cancer Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Wang, S., Yuan, Y., & Liu, S. (2025). Randomized optimal selection design for dose optimization. Biometrics. https://doi.org/10.1093/biomtc/ujaf124

Vancouver

Wang S, Yuan Y, Liu S. Randomized optimal selection design for dose optimization. Biometrics. 2025. doi:10.1093/biomtc/ujaf124

BibTeX
@article{Wang2025,
  author = {Wang, Shuqi and Yuan, Ying and Liu, Suyu},
  title = {Randomized optimal selection design for dose optimization},
  journal = {Biometrics},
  year = {2025},
  doi = {10.1093/biomtc/ujaf124}
}
Kostenlos starten →